349 results on '"Dragovich, Peter S."'
Search Results
2. The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
3. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
4. To Market, to Market—2020: Macromolecular Therapeutics
5. PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
6. To Market, to Market—2019: Macromolecular Therapeutics
7. To Market, to Market—2018: Small Molecules
8. To Market, To Market--2017
9. Data from Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates
10. Supplementary Data from Calicheamicin Antibody–Drug Conjugates with Improved Properties
11. Supplementary Data from An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
12. Supplementary Table 1. Supplementary Figures 1 and 2. from Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates
13. Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
14. PROTACs Targeting BRM (SMARCA2) Afford Selective In VivoDegradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
15. Author response: Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
16. CryoEM reveals unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
17. To Market, To Market--2016
18. Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors.
19. Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase
20. Antibody–Drug Conjugates for Immunology
21. Small-Molecule Lead-Finding Trends across the Roche and Genentech Research Organizations
22. Degrader-antibody conjugates
23. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
24. Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase
25. Efficient synthesis of (1 R,2 S) and (1 S,2 R)-2-aminocyclopentanecarboxylic acid ethyl ester derivatives in enantiomerically pure form
26. Measuring NAD+ levels in mouse blood and tissue samples via a surrogate matrix approach using LC–MS/MS
27. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
28. Calicheamicin Antibody–Drug Conjugates with Improved Properties
29. Regiospecific synthesis of 1,5-disubstituted-1 H-pyrazoles containing differentiated 3,4-dicarboxylic acid esters via Suzuki coupling of the corresponding 5-trifluoromethane sulfonates
30. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
31. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
32. An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
33. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
34. Synthesis of an optically active, bicyclic 2-pyridone dipeptide mimetic
35. Abstract 5687: Selective, chemically-induced degradation of BRM (SMARCA2) enables in vivo efficacy in BRG1 (SMARCA4)-deficient xenograft tumor models
36. Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates
37. Front Cover: Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity (ChemMedChem 1/2020)
38. Improved translation of stability for conjugated antibodies using an in vitro whole blood assay
39. Niobium(III) and (IV) Halide Complexes
40. Formal, stereoselective synthesis of hydroxyethylene dipeptide isosteres utilizing pseudoephedrine amides
41. An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents
42. Spectroscopic and crystallographic characterization of (sigma 2-terpyridyl)Re(CO)3cl. 2D-NMR evidence for a linkage isomerization reaction
43. Studies on the thermal generation and reactivity of a class of (sigma, pi)-1,4-biradicals
44. Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs
45. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
46. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues
47. Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody–Drug Conjugates
48. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes
49. Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo
50. Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.